Cells (Dec 2022)

The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology

  • Isaure Vanmeerbeek,
  • Jannes Govaerts,
  • Raquel S. Laureano,
  • Jenny Sprooten,
  • Stefan Naulaerts,
  • Daniel M. Borras,
  • Damya Laoui,
  • Massimiliano Mazzone,
  • Jo A. Van Ginderachter,
  • Abhishek D. Garg

DOI
https://doi.org/10.3390/cells11233890
Journal volume & issue
Vol. 11, no. 23
p. 3890

Abstract

Read online

Tumour-associated macrophages (TAMs) are essential players in the tumour microenvironment (TME) and modulate various pro-tumorigenic functions such as immunosuppression, angiogenesis, cancer cell proliferation, invasion and metastasis, along with resistance to anti-cancer therapies. TAMs also mediate important anti-tumour functions and can clear dying cancer cells via efferocytosis. Thus, not surprisingly, TAMs exhibit heterogeneous activities and functional plasticity depending on the type and context of cancer cell death that they are faced with. This ultimately governs both the pro-tumorigenic and anti-tumorigenic activity of TAMs, making the interface between TAMs and dying cancer cells very important for modulating cancer growth and the efficacy of chemo-radiotherapy or immunotherapy. In this review, we discuss the interface of TAMs with cancer cell death from the perspectives of cell death pathways, TME-driven variations, TAM heterogeneity and cell-death-inducing anti-cancer therapies. We believe that a better understanding of how dying cancer cells influence TAMs can lead to improved combinatorial anti-cancer therapies, especially in combination with TAM-targeting immunotherapies.

Keywords